Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Accounts Payables (2020 - 2025)

Xeris Biopharma Holdings' Accounts Payables history spans 6 years, with the latest figure at $3.1 million for Q4 2025.

  • For the quarter ending Q4 2025, Accounts Payables rose 34.32% year-over-year to $3.1 million, compared with a TTM value of $3.1 million through Dec 2025, up 34.32%, and an annual FY2025 reading of $3.1 million, up 34.32% over the prior year.
  • Accounts Payables for Q4 2025 was $3.1 million at Xeris Biopharma Holdings, down from $6.5 million in the prior quarter.
  • The five-year high for Accounts Payables was $12.1 million in Q3 2023, with the low at $2.3 million in Q4 2024.
  • Average Accounts Payables over 5 years is $7.5 million, with a median of $6.9 million recorded in 2022.
  • Year-over-year, Accounts Payables surged 208.43% in 2023 and then plummeted 80.2% in 2024.
  • Tracing XERS's Accounts Payables over 5 years: stood at $8.9 million in 2021, then crashed by 48.39% to $4.6 million in 2022, then soared by 151.09% to $11.6 million in 2023, then plummeted by 80.2% to $2.3 million in 2024, then surged by 34.32% to $3.1 million in 2025.
  • Per Business Quant, the three most recent readings for XERS's Accounts Payables are $3.1 million (Q4 2025), $6.5 million (Q3 2025), and $9.5 million (Q2 2025).